Development and Novel Uses of Antibodies in Epithelial Ovarian Cancer
Abstract
Immunologic approaches to treat ovarian cancer, a chemo-sensitive tumor, are in their infancy and have generally represented isolated clinical trial efforts. Further understanding of the host response to epithelial cancers and the potential capability of innovative immunologic technologies to ovarian cancer may play a key role in therapeutic advances. This integrated program proposes to expand the scope of ovarian cancer treatment in general, and immunotherapy in particular by working in three new and interrelated directions. These include: 1) new techniques that may identify relevant new human antibodies and characterize the target antigens, 2) test these in project models to evaluate the potential role in future therapy for ovarian cancer combined with radiation and chemotherapy, and 3) explore their role in allowing for the more accurate targeting of gene therapy. During the second year of the project, we were able to continue projects 1 - 3, culminating in the submission and acceptance of the abstract entitled "The HUI77 Cryptic Epitope is Expressed in Human Ovarian Carcinoma and Regulates Tumor Cell Adhesion and Proliferation in Vitro" at the Society of Gynecologic Oncologists annual meeting.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2004
- Accession Number
- ADA469576
Entities
People
- John P. Curtin
Organizations
- New York University